Aduro Biotech, Inc. (NASDAQ:ADRO) insider Jennifer Lew sold 6,600 shares of Aduro Biotech stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $10.61, for a total value of $70,026.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jennifer Lew also recently made the following trade(s):

  • On Friday, September 1st, Jennifer Lew sold 6,600 shares of Aduro Biotech stock. The shares were sold at an average price of $11.70, for a total value of $77,220.00.
  • On Monday, August 7th, Jennifer Lew sold 6,600 shares of Aduro Biotech stock. The shares were sold at an average price of $12.17, for a total value of $80,322.00.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) traded down 0.89% during mid-day trading on Wednesday, hitting $11.10. The company’s stock had a trading volume of 277,455 shares. The company has a 50-day moving average price of $11.17 and a 200-day moving average price of $10.94. The stock’s market cap is $828.19 million. Aduro Biotech, Inc. has a 1-year low of $8.75 and a 1-year high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The company had revenue of $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. Aduro Biotech’s revenue was down 84.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.03 EPS. Analysts predict that Aduro Biotech, Inc. will post ($1.35) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/04/jennifer-lew-sells-6600-shares-of-aduro-biotech-inc-adro-stock.html.

A number of research analysts have commented on the company. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Cowen and Company assumed coverage on Aduro Biotech in a research note on Tuesday, July 18th. They issued an “outperform” rating on the stock. Zacks Investment Research downgraded Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. HC Wainwright set a $18.00 target price on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 target price on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $19.00.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in shares of Aduro Biotech by 12.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock valued at $388,000 after acquiring an additional 3,769 shares in the last quarter. State Street Corp grew its holdings in shares of Aduro Biotech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after acquiring an additional 52,597 shares in the last quarter. Nexthera Capital LP bought a new position in shares of Aduro Biotech in the 2nd quarter valued at about $1,767,000. PDT Partners LLC bought a new position in shares of Aduro Biotech in the 2nd quarter valued at about $570,000. Finally, Voya Investment Management LLC grew its holdings in shares of Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,515 shares in the last quarter. Institutional investors own 35.05% of the company’s stock.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.